On the morning of March 23, the National Industrial Innovation Center of Precision Medicine was inaugurated in Chengdu Tianfu International Bio-town. West China Hospital of Sichuan University and the cooperative co-construction unit signed the agreement on jointly establishing the National Industrial Innovation Center of Precision Medicine.
The National Industrial Innovation Center of Precision Medicine is led by West China Hospital of Sichuan University, and cooperates with Shanghai Ruijin Hospital, Tsinghua University, Shanghai Pharma Group, BGI Group, Jiangsu Hengrui Pharmaceuticals, Maccura Biotechnology, CDHT Investment and other leading units in the whole industrial chain to construct a collaborative innovation ecosystem, and is committed to building an "aircraft carrier-type" precision medicine industry cluster.
The center is not only the first industrial innovation center in the field of biomedicine in China, but also the only industrial innovation center in the direction of precision medicine.
The President of West China Hospital, Li Weimin, introduced that as the only approved national industrial innovation center in the field of medicine and health, the National Industrial Innovation Center of Precision Medicine will build three key common technology platforms for precise diagnosis, precise treatment, and precise evaluation, and also a precision medicine strategic resource library, to promote scientific and technological innovation, application transformation and industrialization.
According to Sichuan University, it is expected that in the next 3-5 years the center will effectively integrate various innovative resources in the precision medicine industry, and reach the international advanced level in key technical fields such as cell therapy, tumor-targeted new drug and vaccine development, medical 3D printing and artificial intelligence. It will also provide public technical services for the industry, gathers more than 600 cooperation units in industry, academy and research fields. It is expected to obtain more than 1,000 important independent intellectual property rights, driving the output value of the precision medicine industry to exceed CNY 100 billion.
